过去十年中，转化研究和靶向治疗的发展改变了上皮性卵巢癌 (EOC) 的治疗格局。然而，复发性卵巢癌继续对治疗干预提出巨大挑战，需要创新策略来优化治疗结果。目前的研究重点是开发针对 DNA 修复途径潜在耐药途径的药物。然而，其中一些疗法的成本和毒性令人望而却步，并且大多数患者无法参加临床试验。节拍化疗的特点是连续给予低剂量化疗药物，无需长时间治疗中断，已成为一种有前途的方法，其潜在影响超出了复发情况。它主要通过抑制血管生成和激活宿主免疫系统发挥作用。我们在此回顾节拍化疗的作用机制，以及其目前的作用、局限性以及在上皮性卵巢癌治疗中进一步研究的途径。版权所有 © 2023。由 Elsevier B.V. 出版。

Translational research and the development of targeted therapies have transformed the therapeutic landscape in epithelial ovarian cancer (EOC) over the last decade. However, recurrent ovarian cancer continues to pose formidable challenges to therapeutic interventions, necessitating innovative strategies to optimize treatment outcomes. Current research focuses on the development of pharmaceuticals that target potential resistance pathways to DNA repair pathways. However, the cost and toxicity of some of these therapies are prohibitive and majority of patients lack access to clinical trials. Metronomic chemotherapy, characterized by the continuous administration of low doses of chemotherapeutic agents without long treatment breaks, has emerged as a promising approach with potential implications beyond recurrent setting. It acts primarily by inhibition of angiogenesis and activation of host immune system. We here review the mechanism of action of metronomic chemotherapy, as well as its current role, limitations, and avenues for further research in the management of epithelial ovarian cancer.Copyright © 2023. Published by Elsevier B.V.